Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RORB | Q92753 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001832 | 0.84 | CDK1 (0.45) | CDK1CDK4CCND1CDK2HTT | |
| SCHEMBL3248668 | 0.81 | ALDH1A1 (0.42) | MEN1KMT2AHTTRXFP1POLB | |
| SCHEMBL3255380 | 0.79 | CNR2 (0.50) | CNR2MEN1KMT2AHTTRXFP1 | |
| SCHEMBL10899012 | 0.78 | RAB9A (0.56) | CNR2MEN1KMT2AL3MBTL1RORB | |
| SCHEMBL29658169 | 0.78 | CTSD (0.62) | CNR2HTTCTSDNPC1RAB9A | |
| SCHEMBL322168 | 0.78 | CTSD (0.62) | CNR2HTTCTSDNPC1RAB9A | |
| SCHEMBL20892585 | 0.77 | CNR2 (0.58) | CNR2MEN1KMT2ARXFP1RORB | |
| SCHEMBL4979922 | 0.76 | TUBB4A (0.46) | — | |
| SCHEMBL27789892 | 0.76 | CTSD (0.60) | CNR2HTTCTSDNPC1RAB9A | |
| SCHEMBL5001988 | 0.75 | AKR1C3 (0.44) | CDK2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1758871-B1 | PYRAZOLO PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| EP-1758871-B1 | PYRAZOLO PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| EP-1758871-A1 | PYRAZOLO PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121107-A1 | PYRAZOLO PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | DING QINGJIE | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | CDK1, CDK4, CDK2 | CNR2 2750/4885CDK1 1/4885CDK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.